Aileron Shares Fall After Early Data From Chemoprotective Agent In Lung Cancer Setting

  • Aileron Therapeutics ALRN announced interim data from its Phase 1b chemoprotection trial of patients with advanced p53-mutated non-small cell lung cancer (NSCLC) undergoing treatment with first-line carboplatin plus pemetrexed with or without immune checkpoint inhibitors. 
  • ALRN-6924-treated patients could stay on chemotherapy treatment longer, completing 93% of the first four cycles of carboplatin/pemetrexed administered compared to 78% on placebo.
  • This imbalance of completed cycles may have introduced a bias against ALRN-6924 on the composite primary endpoint. 
  • The imbalance increases further when looking at percentages of patients completing six cycles of treatment (79% on ALRN-6924 versus 57% on placebo). 
  • This is reflected in the progression-free survival, which was 4.6 months in the ALRN-6924 arm versus 3.2 months in the placebo arm. 
  • ALRN-6924-treated patients demonstrated 56% of cycles free from serious/severe hematologic toxicities and related events compared to 50% on placebo.
  • Aileron plans to stop further enrollment in the NSCLC trial and apply key learnings to strengthen the Phase 1b breast cancer trial.
  • Additionally, Aileron plans to modify the dosing strategy for the trial and will not further enroll additional patients in the ongoing 0.3 mg/kg and 0.6 mg/kg dose cohorts.
  • Price Action: ALRN shares are down 33.60% at $0.27 during the premarket session on the last check Wednesday.

Posted In: Briefswhy it's movingBiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.